Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Claudin18.2-Targeted CAR-DC and CAR-T in Advanced Colorectal Cancer
NCT06946615Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Whole Cell Cancer Vaccines, CAR-T Cells, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Claudin18.2-targeted Chimeric Antigen Receptor Dendritic Cells and Claudin18.2 CAR-T cells in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Incidence and severity of adverse events at 3 months and Remission Rate at 3 months. Started Apr 2025; status: recruiting.
02
Drugs
Claudin18.2-targeted Chimeric Antigen Receptor Dendritic CellsClaudin18.2 CAR-T cells
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06946615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946615.